Breeze Pod-Based Cannabis Inhalers to Debut in California After Resolve Digital Health Raises $5mm

Article by New Cannabis Ventures

Resolve Digital Health Raises $5 million to Debut the First Standardized Patient Experience for Medical Cannabis

Resolve Digital Health is set to change the way cannabis is prescribed by physicians and experienced by patients with $5 million raised in a Series A round led by Aphria Inc (TSX: APH) (OTC: APHQF) and brokered by Canaccord Genuity Group Inc. This marks the next phase in the company’s development with an upcoming California launch of their debut medical device system, Breeze. The technology behind the product has been in development since 2015, following an initial seed investment with CannaRoyalty Corp. (CSE: CRZ) (OTC: CNNRF).

Unlike existing cannabis products, Breeze provides a more accurate, metered, treatment solution with pre-packaged, single use Smartpod™ filled with the highest quality cannabis buds or oil. The cannabis Smartpod™ is inserted into the Company’s proprietary patent pending vaporizer. The patient experience is tracked through a mobile application with all data securely stored for sharing with doctors, pharmacists and other caregivers.

“Patients have specific needs and clear expectations around how prescribed solutions should address their pain,” Rob Adelson, Founder and CEO of Resolve Digital Health. “The last couple of years have been focused on listening, researching, exploring, testing and ultimately ensuring that our solution is more than just another product option – Breeze represents significant advancements in the consistency, reliability and positive results within the patient experience.”

In recent years, growing awareness of the medical benefits of cannabis has spurred a rapid increase in the number of medicinal users. In Canada, the number of registered medical cannabis patients has increased five-fold in the last eighteen months, and by more than 2.5x in 2016 with a 76% increase in medical patients by March 2016 when compared to the same time just a year prior. By September 2016, there was a 26% increase in registered patients from the previous quarter alone.¹

However, despite a dramatic increase in market awareness and acceptance, there remain numerous barriers to widespread adoption of cannabis as a credible, legitimate replacement or complement to pharmaceutical care. With limited clinical research to validate the respective efficacy of the over 750 strains available, combined with inconsistent physician knowledge of dosing requirements, creates a volatile environment where standardization is needed most. Resolve’s standardized pre-packaged solution is a marked departure from the current unmetered solutions using unknown strains via uncontrolled delivery methods with no process or system to track or monitor dosage and usage.

Read full article here.

About Dankr NewsBot

Beep Boop. I'm just a bot who brings you the dankest news in the biz

Leave a Reply

Powered by Dragonballsuper Youtube Download animeshow